Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 246

Similar articles for PubMed (Select 22523564)

1.

Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.

Li B, Zhang G, Li C, He D, Li X, Zhang C, Tang F, Deng X, Lu J, Tang Y, Li R, Chen Z, Duan C.

PLoS One. 2012;7(4):e34912. doi: 10.1371/journal.pone.0034912. Epub 2012 Apr 16.

2.

[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].

Li B, Zhang GS, Dai CW, Pei MF.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):448-52. Chinese.

PMID:
15854548
3.

Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.

Buitenhuis M, Verhagen LP, Cools J, Coffer PJ.

Cancer Res. 2007 Apr 15;67(8):3759-66.

4.

ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Montano-Almendras CP, Essaghir A, Schoemans H, Varis I, Noël LA, Velghe AI, Latinne D, Knoops L, Demoulin JB.

Haematologica. 2012 Jul;97(7):1064-72. doi: 10.3324/haematol.2011.047530. Epub 2012 Jan 22.

5.

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, Cancelas JA.

Blood. 2006 May 15;107(10):4071-9. Epub 2006 Jan 17.

6.

Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.

Hoermann G, Cerny-Reiterer S, Sadovnik I, Müllauer L, Bilban M, Gröger M, Horny HP, Reiter A, Schmitt-Graeff A, Mannhalter C, Valent P, Mayerhofer M.

Allergy. 2013 Jun;68(6):713-23. doi: 10.1111/all.12139. Epub 2013 Apr 27.

PMID:
23621172
7.

Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.

Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Gajkowska J, Seferyńska I, Hałasz M, Woszczyk D, Markiewicz M, Krzemień S.

Hematol Oncol. 2010 Jun;28(2):93-7. doi: 10.1002/hon.919.

PMID:
19728396
8.

Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.

Kaneko M, Ishihara K, Takahashi A, Hong J, Hirasawa N, Zee O, Ohuchi K.

Int Arch Allergy Immunol. 2007;143 Suppl 1:28-32. Epub 2007 May 1.

PMID:
17541273
9.

Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia.

Kahn JE, Dutoit-Lefevre V, Duban-Deweer S, Chafey P, Pottiez G, Lefranc D, Fain O, Cordier JF, Hatron PY, Bletry O, Prin L.

J Proteome Res. 2011 Apr 1;10(4):1468-80. doi: 10.1021/pr100836p. Epub 2011 Mar 2.

PMID:
21302907
10.

FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.

Crescenzi B, Chase A, Starza RL, Beacci D, Rosti V, Gallì A, Specchia G, Martelli MF, Vandenberghe P, Cools J, Jones AV, Cross NC, Marynen P, Mecucci C.

Leukemia. 2007 Mar;21(3):397-402. Epub 2007 Jan 11.

PMID:
17215855
11.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P.

Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6.

12.

FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.

Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi M, Satoh Y, Shibayama H, Tanaka H, Iwama A, Kanakura Y.

J Biol Chem. 2009 Mar 20;284(12):7719-32. doi: 10.1074/jbc.M807489200. Epub 2009 Jan 14.

13.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

PMID:
19210352
14.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

15.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE.

Blood. 2004 Apr 15;103(8):2879-91. Epub 2003 Nov 20. Review.

16.

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.

Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ.

Chin Med J (Engl). 2008 May 20;121(10):867-73.

PMID:
18706197
17.

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.

Vigna E, Lucia E, Gentile M, Mazzone C, Bisconte MG, Gentile C, Armentano A, Ottaviani E, Rondoni M, Martinelli G, Morabito F.

Cancer Chemother Pharmacol. 2008 Apr;61(4):713-6. Epub 2007 Jun 5.

PMID:
17549478
18.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J.

Blood. 2006 Aug 15;108(4):1374-6. Epub 2006 Apr 27.

19.

[Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].

Zhang Y, Yu MH, Xu SC, Yang L, Yu Y, Hao YS, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):3-8. Chinese.

PMID:
18512307
20.

[Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].

Sekkach Y, Mekouar F, Jira M, Elqatni M, Elomri N, Fatihi J, Badaoui M, Hammi S, Smaali J, El Khattabi A, Amezyane T, Abouzahir A, Ghafir D.

Ann Pharm Fr. 2011 Sep;69(5):277-81. doi: 10.1016/j.pharma.2011.07.004. Epub 2011 Sep 8. French.

PMID:
21924129
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk